Literature DB >> 24418473

Predictors and outcome of low initial forced expiratory volume in 1 second measurement in children with cystic fibrosis.

Gulnur Com1, John L Carroll2, Maria Melguizo Castro2, Xinyu Tang3, Supriya Jambhekar2, Ariel Berlinski2.   

Abstract

OBJECTIVE: To identify the characteristics of children with cystic fibrosis with low initial forced expiratory volume in 1 second (FEV1) % predicted and to investigate their outcome. STUDY
DESIGN: Patients were categorized into low or high initial FEV1 groups using cluster analysis. Comparisons of the demographic and clinical data were performed between the 2 groups.
RESULTS: From 122 children, 21 clustered into the low and 101 into the high FEV1 group. The mean FEV1 was 69% ± 12% predicted for the low and 95% ± 12% predicted for the high FEV1 group (P < .001). The low FEV1 group had lower body mass index percentiles (P = .003), were hospitalized more frequently (P = .001), and had been on dornase alfa longer (P = .006). Low FEV1 group had more patients with positive cultures for Pseudomonas aeruginosa (P = .002) and Stenotrophomonas maltophilia (P < .001) and had more total number of cultures positive for mucoid P. aeruginosa (P = .009) and methicillin resistant Staphylococcus aureus + P. aeruginosa (P = .005). The low FEV1 group continued to have low FEV1 measurements, their FEV1 declined slower, required more hospitalizations per year (P = .01), and had more cultures for mucoid (P = .003) and nonmucoid P. aeruginosa (P = .02) ± methicillin resistant S. aureus (P = .002) in comparison with the high FEV1 group. Poor adherence was associated with lower initial FEV1 values in females, and early, rapid decline of FEV1 in males.
CONCLUSIONS: Some children with cystic fibrosis may present with poor lung function early in life and continue to have subnormal lung function associated with reduced body mass index, more frequent hospitalization, and higher rates of infection. Such children may benefit from careful evaluation and close follow-up.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24418473     DOI: 10.1016/j.jpeds.2013.11.064

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  11 in total

1.  A semiquantitative MRI-Score can predict loss of lung function in patients with cystic fibrosis: Preliminary results.

Authors:  Juergen F Schaefer; Andreas Hector; Katharina Schmidt; Matthias Teufel; Sabrina Fleischer; Ute Graepler-Mainka; Joachim Riethmueller; Sergios Gatidis; Susanne Schaefer; Konstantin Nikolaou; Dominik Hartl; Ilias Tsiflikas
Journal:  Eur Radiol       Date:  2017-06-29       Impact factor: 5.315

2.  Pseudomonas aeruginosa PA14 Enhances the Efficacy of Norfloxacin against Staphylococcus aureus Newman Biofilms.

Authors:  Giulia Orazi; Fabrice Jean-Pierre; George A O'Toole
Journal:  J Bacteriol       Date:  2020-08-25       Impact factor: 3.490

3.  Coculture of Staphylococcus aureus with Pseudomonas aeruginosa Drives S. aureus towards Fermentative Metabolism and Reduced Viability in a Cystic Fibrosis Model.

Authors:  Laura M Filkins; Jyoti A Graber; Daniel G Olson; Emily L Dolben; Lee R Lynd; Sabin Bhuju; George A O'Toole
Journal:  J Bacteriol       Date:  2015-04-27       Impact factor: 3.490

4.  Outcomes and Safety of Outpatient Parenteral Antimicrobial Therapy in Select Children with Cystic Fibrosis.

Authors:  Gulnur Com; Amit Agarwal; Shasha Bai; Zhuopei Hu; Grace Goode; Hollyn McCarty; Ariel Berlinski
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-12-11       Impact factor: 1.349

5.  Mechanisms of Pyocyanin Toxicity and Genetic Determinants of Resistance in Staphylococcus aureus.

Authors:  Michael J Noto; William J Burns; William N Beavers; Eric P Skaar
Journal:  J Bacteriol       Date:  2017-08-08       Impact factor: 3.490

6.  Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis.

Authors:  Tavs Qvist; David Taylor-Robinson; Elisabeth Waldmann; Hanne Vebert Olesen; Christine Rønne Hansen; Inger Hee Mathiesen; Niels Høiby; Terese L Katzenstein; Rosalind L Smyth; Peter J Diggle; Tania Pressler
Journal:  J Cyst Fibros       Date:  2015-10-09       Impact factor: 5.482

7.  Increased Expression of Plasma-Induced ABCC1 mRNA in Cystic Fibrosis.

Authors:  Justin E Ideozu; Xi Zhang; Amy Pan; Zainub Ashrafi; Katherine J Woods; Martin J Hessner; Pippa Simpson; Hara Levy
Journal:  Int J Mol Sci       Date:  2017-08-11       Impact factor: 5.923

8.  Anaerobiosis influences virulence properties of Pseudomonas aeruginosa cystic fibrosis isolates and the interaction with Staphylococcus aureus.

Authors:  Ross Pallett; Laura J Leslie; Peter A Lambert; Ivana Milic; Andrew Devitt; Lindsay J Marshall
Journal:  Sci Rep       Date:  2019-05-01       Impact factor: 4.379

9.  Pseudomonas aeruginosa Increases the Sensitivity of Biofilm-Grown Staphylococcus aureus to Membrane-Targeting Antiseptics and Antibiotics.

Authors:  Giulia Orazi; Kathryn L Ruoff; George A O'Toole
Journal:  mBio       Date:  2019-07-30       Impact factor: 7.867

10.  Pseudomonas aeruginosa Alters Staphylococcus aureus Sensitivity to Vancomycin in a Biofilm Model of Cystic Fibrosis Infection.

Authors:  Giulia Orazi; George A O'Toole
Journal:  MBio       Date:  2017-07-18       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.